Skip to main content
  • Loading metrics

If You Could Only Choose Five Psychotropic Medicines: Updating the Interagency Emergency Health Kit

  • Mark van Ommeren ,

    Affiliation Department of Mental Health and Substance Abuse, World Health Organization (WHO), Geneva, Switzerland

  • Corrado Barbui,

    Affiliation WHO Collaborating Centre for Research and Training in Mental Health, Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy

  • Kaz de Jong,

    Affiliation Médecins Sans Frontières-Holland (MSF-H, Doctors without Borders-Holland), Amsterdam, The Netherlands

  • Tarun Dua,

    Affiliation Department of Mental Health and Substance Abuse, World Health Organization (WHO), Geneva, Switzerland

  • Lynne Jones,

    Affiliation International Medical Corps (IMC), Santa Monica, California, United States of America

  • Pau Perez-Sales,

    Affiliation Medicos del Mundo España (MdM-E, Doctors of the World-Spain), Madrid, Spain

  • Marian Schilperoord,

    Affiliation Senior Public Health Officer, Public Health and HIV Section, United Nations High Commissioner of Refugees (UNHCR), Geneva, Switzerland

  • Peter Ventevogel,

    Affiliation HealthNet TPO, Amsterdam, The Netherlands

  • M. Taghi Yasamy,

    Affiliation Department of Mental Health and Substance Abuse, World Health Organization (WHO), Geneva, Switzerland

  • Shekhar Saxena

    Affiliation Department of Mental Health and Substance Abuse, World Health Organization (WHO), Geneva, Switzerland

Summary Points

  • The Interagency Emergency Health Kit is a box with medicines and medical supplies designed to meet the expected primary health care needs of people exposed to major humanitarian emergencies.
  • Previous editions of the kit have been inadequate to help people with severe mental or neurological disorders.
  • The challenge to be addressed was to propose the inclusion of one medicine for each of five classes of psychotropic medicines.
  • Amitriptyline (tablets), haloperidol (tablets and injections), diazepam (tablets and injections), biperiden (tablets), and phenobarbital (tablets) will be included in the next edition of the kit.
  • A fundamental inequity has been addressed by ensuring that the availability of medicines for people with severe mental and neurological disorders will be on a par with that for other medical disorders in emergencies.


The Interagency Emergency Health Kit (IEHK) [1] is a large, pre-packed box containing medicines and medical supplies (Table 1). The kit is designed to meet the expected primary health care (PHC) needs of persons exposed to acute humanitarian crises caused, for example, by forced displacement or major natural disaster such as an earthquake, cyclone, or tsunami. Such events often involve the partial or complete destruction of locally available medicines. The IEHK aims to provide sufficient medicines and supplies for medical care for a population of 10,000 people—located in one geographical area or place—for 3 months. The next version of the IEHK will be the fourth edition of the one originally developed three decades ago [2],[3]. While data on this new IEHK are not yet available, the third edition came in a very heavy, large box (1,045 kg, 4.6 m3) containing ten basic kits and one supplementary kit [4]. The IEHK is held in stock by major suppliers of generic medicines, most of whom ship it within 48 hours after being ordered by an aid agency (Figure 1).

Figure 1. Cyclone Nargis response 2008: Interagency Emergency Health Kits en route to Myanmar.

Photo credit: Fred Urlep, WHO.

Table 1. Psychotropics in the next edition of the Interagency Emergency Health Kit [1].

The IEHK has become a core feature of international emergency response whenever medical facilities and pharmacies have been destroyed or populations have been displaced. Medical relief agencies tend to immediately allocate emergency funds to procure kits. These kits typically play a major role very early in sudden-onset emergencies when the exact medical needs of the population, the health services situation, and human resource capacities are largely unknown. Once local needs and resources have been assessed, standard orders of IEHKs tend to be replaced—as they should—with situation-specific orders of medicines and supplies.

The IEHK ensures continuity in the supply of medicines, most of which are life-saving. It addresses at least three emergency-relief management challenges: (a) managing the procurement, distribution, and logistics of supplies in an efficient manner; (b) focusing the good intent of donors of medicines and medical devices on a small variety of essential products rather than flooding systems with a large variety of unknown products, including expensive, non-essential, expired, or poorly labelled ones; and (c) harmonizing use of different medicines by different organizations for the same conditions across the health system [5],[6].

The IEHK is not a mini-pharmacy. Its purpose is to allow for a response in the acute phase of emergencies before any needs assessment results becomes available. Given that its size is limited to allow for easy transport, the kit involves a compromise, providing a limited range and number of medicines that are considered priority to meet the needs of populations with disrupted medical facilities. All medicines in the kit are on the WHO Model List of Essential Medicines [7] (WHO Model List). This is a prioritized list of over 350 medicines selected through a transparent, rigorous review of the evidence that considers the public health relevance, efficacy, safety, and cost-effectiveness of different medicines. The WHO Model List is used by many countries as a basis for deciding what medicines should be on their national list of essential medicines, which guides (amongst other things) procurement and supply of medicines for local PHC services. The IEHK, however, can only include only a fraction of the medicines on the WHO Model List. The 2011 version of the IEHK will contain 73 medicines.

Psychotropic Medicines in the IEHK

Medical care for people with severe mental or neurological disorders has, historically, not been a priority in humanitarian crises, but this is changing [8]. One major impetus for change has been the Inter-Agency Standing Committee (IASC) Guidelines on Mental Health and Psychosocial Support in Emergency Settings [9], which was developed through an extensive consultation process. The Guidelines were released by a committee of United Nations (UN) and non-UN international humanitarian agencies responsible for humanitarian policy according to UN General Assembly resolution 46/182. The Guidelines describe minimum responses during emergencies and cover a wide range of mostly social interventions for the population at large as well as psychological first aid for people experiencing acute distress. In addition, these IASC guidelines emphasize the protection of and care for people with severe mental disorders as a priority in acute emergencies.

The IEHK has been inadequate with respect to psychotropics. For example, the third (2006) edition included only three psychotropic medicines (chlorpromazine injections, diazepam injections, phenobarbital tablets), which do not cover first-line treatment of depression and psychosis. The IASC Guidelines stipulate that the minimum provision of medicines in emergency health kits should include—in tablet form—at least one anti-depressant, one anxiolytic, one anti-psychotic, one anti-Parkinsonian (to deal with extra-pyramidal side effects of anti-psychotic medicines), and one anti-epileptic medicine.

In 2009, the authors submitted an inter-agency proposal to suggest changes to the psychotherapeutic and antiepileptic medicines classes of the IEHK. This proposal was shaped by two considerations. First, given that the IEHK is meant to be a subset of medicines of the WHO Model List, the proposal was limited to selecting from the few psychotropic medicines on that list (Table 2). Second, given that the previous IEHK only had 67 medicines to address all priority health conditions relevant to PHC in emergency settings, the selection of additional medicines needed to be proportionate: one medicine for each of the classes of psychotropic medicines. The proposal—described in this article—was approved by the independent, inter-agency Review Committee for Updating the Interagency Emergency Health Kit, which consists of public health experts overseeing the IEHK update. Medicines from each of the aforementioned five classes of psychotropic medicines will be included in the next edition of the IEHK.

Table 2. The WHO Model List of Essential Medicines and the Interagency Emergency Health Kit (IEHK).

Choice of Anti-Depressant

Fluoxetine and amitriptyline are the only anti-depressant medicines on the WHO Model List. After review of the advantages and disadvantages (Table 3) of these two similarly effective medicines [10],[11], amitriptyline was selected. The overriding consideration was the need to be consistent with what is most likely to be available currently in most low-income country PHC systems to maximize continuity of care and build on local PHC capacities. Compared to fluoxetine, amitriptyline is more widely available in PHC systems in emergency-prone Africa [12].

Table 3. Advantages and disadvantages of including fluoxetine versus amitriptyline in the Interagency Emergency Health Kit (IEHK).

Selecting amitriptyline is consistent with the IASC Guidelines, which recommends the use of medicines that are on the country's essential medicines list [8]. Fluoxetine was only added to the WHO Model List in 2007. We expect that in future years fluoxetine will slowly be added to many countries' national list of essential medicines and accordingly will become widely available in Africa as well. We envision that future updates of the kit —possibly as early as the fifth edition in 2015—will involve replacing amitriptyline with fluoxetine, because fluoxetine is easier to prescribe and is more suitable for a broader range of age groups (e.g., from adolescence to old age). Of note, the evidence on these two medicines for use in post-traumatic stress disorder is inconclusive [13] and did not influence the selection.

Choice of Anxiolytic

A small supply of diazepam tablets will be added to the kit. The only anxiolytics on the WHO Model List are diazepam (in tablet and injectable form) and lorazepam (in injectable form). People presenting with normal (non-pathological), acute anxiety are numerous in the early phases of all emergencies. Non-pharmacological measures (e.g., psychological first aid) should be used. Psychological first aid involves basic, non-intrusive pragmatic care with a focus on listening but not forcing talk; assessing needs and concerns; ensuring that basic needs are met; encouraging social support from significant others; and protecting from further harm [9]. Anxiolytics in the form of benzodiazepines may slow down recovery from traumatic stress [14], can produce dependence, and tend to be prescribed indiscriminately in many emergencies. While precautions should be taken to prevent the routine prescription of benzodiazepines to people experiencing distress in emergencies [15], there are occasions when anxiolytics are indicated. For example, they are appropriate in cases of severe agitation or sleeplessness that interfere with a person's ability to address their own and their family's survival needs, and that do not respond to non-pharmacological interventions. The availability of injectable diazepam in previous editions of the kit has meant that on many occasions acutely anxious individuals were treated with injections of diazepam. This is not the first-line route of administration in anxiety reactions, and this encourages frequent returns to the already overburdened emergency health care provider. When combined with psychological first aid and culturally relevant relaxation methods, dispensing a few days of diazepam tablets can be humane and appropriate to lessen agitation and restore sufficient sleep to help a severely distressed person through a crisis. Injectable diazepam will be kept in the kit for the management of status epilepticus.

Choice of Anti-Psychotic

Injectable chlorpromazine—which was in the previous edition of the kit—will be replaced with haloperidol in both injectable and tablet form. Anti-psychotic tablets will be added for a number of reasons. Although injections can be used, oral administration is preferred in chronic psychosis, which may occur throughout an extended humanitarian emergency. Tablets also have the advantage that they can be provided by family members after prescription by very busy health staff. Oral haloperidol is preferred to oral chlorpromazine because, despite similar efficacy, randomized evidence suggests that the former is associated with better acceptability rates [16]. With respect to injectable anti-psychotics, National Institute for Health and Clinical Excellence (NICE) Guidelines recommend against rapid tranquillization using chlorpromazine, highlighting a number of side effects including acting as a local irritant if given intramuscularly [17]. Accordingly, chlorpromazine injections will be replaced with haloperidol tablets and injections.

Choice of Anti-Parkisoninan

Anti-cholinergic medicines need to be available to counteract movement disorders (such as Parkinsonism and acute dystonia) that can occur as side effects of anti-psychotic medicines [18]. A Cochrane review [19] reported that 33% of patients on haloperidol develop movement disorders and need anti-cholinergic medication. Biperiden and levodopa/carbidopa are the two anti-Parkinsonian medicines on the WHO Model List. Levodopa/carbidopa is generally not used in mental health to treat the side effects of anti-psychotics, so biperiden was suggested.

Choice of Anti-Epileptic

Phenobarbital continues to be in the kit, because it is by far the most commonly available anti-epileptic medicine in low-income countries [20], by far the least expensive, and by far the most cost-effective [21]. Tolerability of phenobarbital tends to be adequate [22], and it is promoted through the Global Campaign Against Epilepsy by WHO, the International League against Epilepsy, and the International Bureau for Epilepsy. However, the 100-mg tablet in the previous kit is too large for the treatment of children (even when one breaks the tablet), so the tablet weight will be reduced to 50 mg to make it available for children.

There is a caveat to the inclusion of phenobarbital and diazepam in the kit, and that is that these are controlled medicines requiring import authorization from national authorities [23]. This causes significant delays in delivery of the kit, as national authorities tend to be overwhelmed in emergencies. To address this challenge, suppliers of the IEHK tend to offer the option of buying the kit without controlled psychotropics or narcotics [4]. While some offer to substitute narcotics with tramadol (an analgesic that is not controlled), they do not offer substitutes for phenobarbital and diazepam. Although we are not aware of a good non-controlled alternative medicine to diazepam, drug suppliers may consider substituting phenobarbital with carbamazepine. The latter is much more expensive, but it is an effective anti-convulsant that is on the essential medicines list of almost all countries [20]. Carbamazepine should be importable given that it is not controlled.


The changes to the IEHK described in this article have addressed a fundamental inequity. In emergencies, PHC professionals will now be in a position to provide medical treatment to people with severe mental or neurological disorders on a par with treatment for other medical conditions, because psychotropic medicines will be available in emergencies.

Some observers may argue that the IEHK should be limited to life-saving medicines, but such reasoning is not in line with current thinking. For example, the influential Sphere Project [24] promotes the principle of survival with dignity through its widely endorsed handbook. Although many people with severe mental disorders tend to not experience dignified life conditions even before a conflict or other disaster strikes (e.g., in terms of housing conditions or work opportunities), their life conditions tend to worsen dramatically during emergencies.

When left untreated, these disorders put people at substantial risk of death in the midst of an emergency [8]. People with psychosis have been known to be shot in conflict situations because of not comprehending instructions by soldiers. Alternatively, many have been abandoned by family members when there is population movement. Parents with severe depression in emergencies have neglected to take care of themselves or feed and provide care to their children. Also, people who were treated with anti-epileptics before the emergency face a fatal risk if there is a sudden discontinuation of supply of anti-epileptics due to the emergency. Finally, mental and neurological disorders are associated with elevated mortality rates [25].

Many specialists in psychiatry and neurology will likely argue that the inclusion of just one medicine of each of the classes of psychotropic medicines is insufficient. They may experience it as unacceptable that the vast arsenal of medicines available in modern specialist care is reduced to a handful of first-generation drugs. However, the IEHK has to be limited in size to be feasibly made available during acute emergencies.

In humanitarian emergencies that affect large numbers of people, it is necessary to apply a population-wide perspective to use all available means to address the health status of the maximum number of people. This requires priority setting, which involves making difficult choices. Including one medicine from each of five classes of psychotropic medicines in the IEHK has involved tough priority setting but has been a major step towards the agreed goal of providing minimum care for people with severe mental and neurological disorders in emergencies [9].


The proposal on the inclusion of psychotropic medicines in the IEHK has benefitted from suggestions by Dr. Renato Souza (Mental Health Advisor, MSF Switzerland) and by the Review Committee for Updating the Interagency Emergency Health Kit. We thank the Committee's Secretary, Dr. Helene Moller, (WHO, Department of Essential Medicines and Pharmaceutical Policies) for guiding us through the application process and for helpful comments on a previous version of this article.

Author Contributions

Wrote the first draft: MvO. Contributed to the writing of the paper: MvO CB TD LJ KdJ PP-S MS PV TY SS. ICMJE criteria for authorship read and met: MvO CB TD LJ KdJ PP-S MS PV TY SS. Agree with the manuscript's results and conclusions: MvO CB TD LJ KdJ PP-S MS PV TY SS.


  1. 1. WHO (2011) The Interagency Emergency Health Kit 2011: medicines and medical devices for 10,000 people for approximately 3 months. Fourth edition. Geneva: WHO. In press.
  2. 2. Hogerzeil HV (1990) Emergency health kits. Lancet 336: 1194.
  3. 3. Simmonds SP, Walker GJA (1982) Essential drugs for primary health care standard packages. Lancet 1(8269): 435–436.
  4. 4. WHO (2007) Emergency kits used by WHO: description and specifications. Geneva: WHO. Available: Accessed 28 March 2011.
  5. 5. Pinheiro CP (2008) Drug donations: what lies beneath. Bull World Health Organ 86: 580.
  6. 6. Simmonds S, Mamdani M (1988) Essential drug lists and health relief management. Trop Doct 18: 155–158.
  7. 7. WHO (2009) Model list of essential medicines. 16th edition. Geneva: WHO.
  8. 8. Jones L, Asare JB, El Masri M, Mohanraj A, Sherief H, et al. (2009) Severe mental disorders in complex emergencies. Lancet 374: 654–661.
  9. 9. Inter-Agency Standing Committee (IASC) (2007) Guidelines on mental health and psychosocial support in emergency settings. Geneva: IASC.
  10. 10. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, et al. (2005) Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005: CD004185.
  11. 11. Guaiana G, Barbui C, Hotopf M (2007) Amitriptyline for depression. Cochrane Database Syst Rev 2007: CD004186.
  12. 12. Health Action International (2010) Survey results. Available: Accessed 28 March 2011.
  13. 13. Bisson JI (2010) Post-traumatic stress disorder. Clin Evid (Online) 02: 1005.
  14. 14. Freeman C (2003) Drugs and physical treatment after trauma. In: Ørner R, Schnyder U, editors. Reconstructing early intervention after trauma. Oxford: Oxford University Press. pp. 169–176.
  15. 15. Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S (2008) Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev 2008: CD004278.
  16. 16. van Ommeren M, Saxena S, Saraceno B (2005) Mental and social health during and after acute emergencies: emerging consensus? Bull World Health Organ 83: 71–75.
  17. 17. National Collaborating Centre for Nursing and Supportive Care (2005) Violence: the short-term management of disturbed/violent behaviour in psychiatric in-patient settings and emergency departments. London: National Institute for Clinical Excellence (NICE).
  18. 18. WHO (2010) mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings. Geneva: WHO. Available: Accessed 28 March 2011.
  19. 19. Irving CB, Adams CE, Lawrie S (2006) Haloperidol versus placebo for schizophrenia. ochrane Database Syst Rev 2006: CD003082.
  20. 20. WHO (2004) Atlas: Country resources for neurological disorders. Geneva: WHO.
  21. 21. Chisholm D (2005) Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis. Epilepsia 46: 751–759.
  22. 22. Kwan P, Brodie MJ (2004) Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45: 1141–1149.
  23. 23. International Narcotics Control Board (2003) List of psychotropic substances under international control. Vienna: Vienna International Centre. Available: Accessed 28 March 2011.
  24. 24. Sphere Project (2011) Humanitarian charter and minimum standards in disaster response. Geneva: Sphere Project.
  25. 25. Prince M, Patel V, Saxena S, Maj M, Maselko J, et al. (2007) No health without mental health. Lancet 370: 859–877.
  26. 26. WHO (2006) Dollars, DALYs and decisions: economic aspects of the mental health system. Geneva: WHO.